92249-24-6

Basic information

• Product Name: (4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one
• Synonyms: 2-methyl-4-(3,4,5-trimethoxybenzylidene)-4,5-dihydro-1,3-oxazol-5-one
• CAS NO: 92249-24-6
• Molecular Formula: C₁₄H₁₅NO₅
• Molecular Weight: 277.2726
• Mol File: 92249-24-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 403.7°C at 760 mmHg
• Flash Point: 179.4°C
• Density: 1.22g/cm³
• Vapor Pressure: 9.96E-07mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: (4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one(92249-24-6)
• EPA Substance Registry System: (4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one(92249-24-6)

Safety Data

• Hazardous Substances Data: 92249-24-6(Hazardous Substances Data)

Usage

General Description

(4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one is a chemical compound with a molecular formula C16H17NO5. It is a heterocyclic organic compound containing an oxazole ring and a benzylidene substituent. (4Z)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1,3-oxazol-5(4H)-one has potential applications in pharmaceuticals and agrochemicals due to its biological activity. Its structural features make it a useful molecule for medicinal chemistry and drug development. The presence of the benzylidene group and the oxazol-5(4H)-one scaffold could make it a promising candidate for the development of new pharmaceuticals with therapeutic properties. Further research is needed to understand the full potential and applications of this compound.

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 543-24-8 N-acetylglycine 
• 108-24-7 acetic anhydride 
• 56-40-6 glycine 

Downstream Products

• 16364-49-1 N-<α-Acetamino-3.4.5-trimethoxycinnamoyl>-L-Glu 
• 82317-75-7 rac-methyl 2-acetamido-3-(3,4,5-trimethoxyphenyl)propanoate 
• 76774-04-4 2-Hydroxy-3-(3,4,5-trimethoxy-phenyl)-propionic acid 
• 87293-13-8 α-acetamido-3,4,5-trimethoxycinnamic acid 
• 1575728-70-9 1-(4-chloro-6-methylpyrimidin-2-yl)-2-phenyl-4-(3,4,5-trimethoxybenzylidene)-1H-imidazol-5(4H)-one 
• 1575728-32-3 1-(4-chloro-6-methylpyrimidin-2-yl)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1H-imidazol-5(4H)-one 
• 1575728-09-4 1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-phenyl-4-(3,4,5-trimethoxybenzylidene)-1H-imidazol-5(4H)-one 
• 1575727-66-0 1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-methyl-4-(3,4,5-trimethoxybenzylidene)-1H-imidazol-5(4H)-one 
• 1373956-80-9 2-methyl-1-(pyridin-4-ylmethyl)-4-(3,4,5-trimethoxybenzylidene)-1H-imidazol-5(4H)-one 
• 1228431-79-5 C₂₉H₂₆N₄O₅ 
• 143815-54-7 (Z)-2-Hydroxy-3-(3,4,5-trimethoxy-phenyl)-acrylic acid 
• 51221-30-8 2-Amino-3-(3,4,5-trimethoxy-phenyl)-propionic acid; hydrochloride 
• 82337-59-5 N-Acetyl-3.4.5-trimethoxyphenylalanin 

Relevant articles and documents

Activated carbon/Br?nsted acid-promoted aerobic benzylic oxidation under “on-water” condition: Green and efficient synthesis of 3-benzoylquinoxalinones as potent tubulin inhibitors

Green chemistry is becoming the favored approach to preparing drug molecules in pharmaceutical industry. Herein, we developed a clean and efficient method to synthesize 3-benzoylquinoxalines via activated carbon promoted aerobic benzylic oxidation under “on-water” condition. Moreover, biological studies with this class of compounds reveal an antiproliferative profile. Further structure modifications are performed and the investigations exhibited that the most active 12a could inhibit the microtubule polymerization by binding to tubulin and thus induce multipolar mitosis, G2/M phase arrest, and apoptosis of cancer cells. In addition, molecular docking studies allow the rationalization of the pharmacodynamic properties observed. Our systematic studies provide not only guidance for applications of O2/AC/H2O system, but also a new scaffold targeting tubulin for antitumor agent discovery.

3-(3,4,5-trimethoxy benzoyl)quinoxaline derivative and application thereof

The invention belongs to the technical field of medicines, relates to a 3-(3,4,5-trimethoxy benzoyl)quinoxaline derivative and an application thereof, and specifically, relates to a compound of the derivative, and an application of the compound as a tumor cell proliferation inhibitor in preparing an anti-tumor medicine. The structural formula of the compound provided by the invention is as shown in the specification, in the formula, R, R1 and R2 are described as the claims and the specification.

Synthesis, in-vitroreverse transcriptase inhibitory activity and docking study of some new imidazol-5-one analogs

Non-nucleoside reverse transcriptase inhibitors have a definitive role and most commonly used in treatment of HIV-1 infection. A new series of 4-ethylidene/substituted-benzylidene-1-(4-hydroxy/chloro-6-methylpyrimidin-2-yl) -2-ethyl/phenyl-1H-imidazol-5(4H)-one were designed, synthesized, and evaluated for HIV-1 reverse transcriptase (RT) inhibitory activity. The results of in-vitro HIV-1 RT assay showed that some of the new compounds, such as 4c, 4d, 4e, 5a, and 5e effectively inhibit HIV-1 RT activity. 1-(4-Chloro-6- methylpyrimidin-2-yl)-4-(furan-2-ylmethylene)-2-methyl-1H-imidazol-5(4H)-one (5e) exerted most potent in-vitro HIV-1 RT inhibitory activity, among the group of compounds. Molecular docking studies were carried out to explore the binding affinity of imidazole-5-one analogs in active site of HIV-1 RT enzyme. Springer Science+Business Media 2014.